Qianjin Capsule of Gynaecology
ApprovedSmall molecule
Qianjin Capsule of Gynaecology is one of 11 small molecule programs targeting Pelvic Inflammatory Disease. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Pelvic Inflammatory Disease
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Flagyl
DDePuy Orthopaedics
Approved
Levaquin
WWim Janssens
Approved
Floxin
WWim Janssens
Phase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Avelox
BayerPhase 3
Morinidazole
Jiangsu Hansoh Pharmaceutical Co., Ltd.Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Rocephin
CConrado Roberto Hoffmann Filho
Phase 2
Qianjin Capsule of Gynaecology
CChina Academy of Chinese Medical Sciences
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details